Experience The Nirvana CBD Difference

Free Shipping on All Orders Over $50

Enjoy A Broad Spectrum Of CBD Products.

Featuring a wide selection of ultra-premium, lab-tested CBD products–including CBD oils, topicals, gummies, and softgels–Nirvana CBD is the leader in high-quality CBD!


About Nirvana CBD
Nirvana CBD was founded in 2017 with an emphasis on honest core values. Yet, Nirvana CBD is more than just a product and far more than just a company, they are a team of talented individuals and a family who deeply care for the well-being of others. They aim to provide natural relaxation for consumers.



Get new content delivered directly to your inbox.

Nevada Leads The Way For Veterinarians To Treat Pets With CBD

Starting this October, veterinarians licensed in Nevada can recommend and administer hemp and cannabidiol products containing not more than 0.3% tetrahydrocannabinol without fear of sanction from the state licensing board.

Earlier this year, Gov. Steve Sisolak signed Assembly Bill 101, making Nevada the first state to legalize the use of cannabinoids as a veterinary treatment. The Nevada Board of Veterinary Medical Examiners helped write AB 101, which the Nevada VMA supported, according to NVMA Executive Director Michelle Wagner.

The bill’s sponsor, State Assemblyman Steve Yeager, introduced the measure in February because Nevada law was unclear about whether veterinarians were permitted to administer CBD products or discuss them with pet owners.

“Because of the ambiguity in our law, I learned that many veterinarians chose not to talk about CBD with pet owners for fear of being disciplined,” Yeager said. “This left pet owners in a tough spot because CBD products are generally unregulated, and it would be difficult for a pet owner to know exactly what to purchase or administer without the professional advice of a veterinarian.”

Nevada voters approved medical marijuana for people by ballot initiative in 2000. Cannabis became legal for recreational use in the state on Jan. 1, 2017, following a 2016 ballot measure.

AB 101 encountered no opposition and passed the state Assembly and Senate without a single no vote, Yeager explained.

“I certainly hope that other states follow Nevada’s lead and provide reassurances to licensed veterinarians that they can administer CBD or talk about it with patients without fear of facing disciplinary proceedings,” he said. “The bill itself is fairly simple and, thus, is a good model for other states.”

Although products containing 0.3% or less THC are exempted from the federal Controlled Substances Act, the products do fall under the Federal Food, Drug, and Cosmetic Act if they are used therapeutically or included in animal food. The Food and Drug Administration considers the therapeutic use of these products to be the use of unapproved drugs.

A Simple Question

But do medical cannabinoids actually help animal patients?

It’s a deceptively simple question at the heart of an animal health concern complicated by a tangle of federal and state regulations, research challenges, and species-specific pharmacokinetics.

Dr. Dawn Boothe is a professor of veterinary physiology and pharmacology at Auburn University studying cannabis’s potential as a veterinary treatment. She sought to make sense of the issues during her presentation “Medical Cannabinoids Revisited” at AVMA Virtual Convention 2021 on Aug. 1.

The cannabis sativa plant contains more than 90 unique compounds, or cannabinoids, including CBD and THC, as well as almost 500 other terpenoids and phenylpropanoids. For several millennia, humans have used cannabinoids for pain, epilepsy, gastrointestinal disorders, and even infections.

Dr. Boothe said research interest in the therapeutic use of cannabis in the United States essentially came to a “screeching halt” in 1971 with the federal Controlled Substances Act, which listed cannabis as a Schedule 1 drug, meaning the federal government regarded cannabis as having no therapeutic properties and a high potential for abuse.

“That’s changed in the last couple of decades as, increasingly, states are paying attention to medical cannabinoids,” Dr. Boothe said. “But I do shudder to think sometimes about how much we would have learned if we had taken a different path in our reaction to cannabis.”

The federal government’s position on cannabis has somewhat softened in recent years, most notably with the 2018 Farm Bill’s removal of industrial hemp containing 0.3% or less of THC from the Controlled Substances Act. That said, the use, sale, and possession of cannabis over 0.3% THC, despite laws in many states permitting it under various circumstances, is illegal under federal law.

Making Sense of It All

The restrictions on veterinarians haven’t diminished interest among pet owners, who have available to them a veritable pharmacopeia of CBD products claiming to treat any number of animal ailments and behavioral problems.

None of the products are approved by the FDA, which, as Dr. Boothe explained, raises concerns about variability in cannabinoid concentrations, mislabeling, and contamination with harmful additives, such as fentanyl or synthetic cannabinoids.

“If you’re looking for a product that has a certificate of analysis that you can have faith in—as I would—go to the USDA (U.S. Department of Agriculture) website and look at the laboratories that the DEA (Drug Enforcement Administration) has approved as being appropriate for analysis of hemp crops,” Dr. Boothe said. “That at least can increase the level of validity for that product.”

Then there are questions about what constitutes a therapeutic dose of cannabinoid in a particular species as well as which formulations actually deliver that dose to the animal patient. There’s evidence that, in dogs, the route of CBD administration, such as in a soft capsule containing oil, may increase the oral bioavailability, according to Dr. Boothe.

“Hemp seed oil, sesame seed oil, and medium-chain triglycerides are the most common oils that are being used,” she said. “We need to see data demonstrating the differences in oral bioavailability among these different compounds.”

Cats are more challenging. “We’re going to have to have some good pharmacokinetic studies providing us information about dosing and cats,” Dr. Boothe said. “We have demonstrated that in cats there is variability in absorption, but, as in dogs, feeding will enhance that absorption.”

Dogs appear to tolerate CBD far better than THC, which was shown to cause ataxia when administered intravenously in smaller, less-concentrated doses than CBD. Dogs were also found to build a tolerance to cannabinoids over time.

Continue Reading On American Veterinary Medical Association

Recent Cannabis Articles

Get new content delivered directly to your inbox.

CBD Product Market Will Reach Over $210 Billion By 2028

Yahoo! Finance | This research report provides an in-depth analysis of the CBD-infused products market across five major geographies and emphasizes on the current market trends, market size, market shares, recent developments, and forecast till 2028. The CBD-infused Products Market is expected to reach $216.8 billion by 2028, at a CAGR of 45.6% during the forecast period, 2021-2028.

The growth of this market is mainly attributed to the rising demand and increasing legalization of cannabis, growing application of cannabis in cancer, and health benefits offered by cannabis-infused products are also a few of the key factors driving the growth of the CBD-infused products market.


The study offers a comprehensive analysis of the CBD-infused products market with respect to the source (hemp and marijuana), type (CBD-edibles {confectionery products, bakery products, beverages [non-alcoholic beverages and alcoholic beverages], coffee & tea products, and other products}, CBD-oil and extracts, CBD-personal care products {skincare products, haircare products, deodorants and perfumes, and other personal care products}, CBD-smoke & vape products, CBD-supplements, CBD-pet products, and other CBD-products), distribution channel (offline store {dispensary, pharmacies, natural health foods store, and other stores} and online store), and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on source, the CBD-infused products market is mainly segmented into hemp and marijuana. The hemp segment is estimated to account for the largest share of the CBD-infused products market in 2021. The large share of this segment is mainly attributed to its lower THC concentrations, which decrease or eliminate its psychoactive effects and increase hemp-derived products for various medical applications. Also, its anti-inflammatory, anti-aging, antioxidant properties, and high effectiveness of CBD extracted from hemp is a key factor for the large share of this segment. However, it is also expected to witness significant growth, as some governments regulate the concentration of THC and permit only hemp with an especially low THC content.

Based on type, the CBD-infused products market is segmented into CBD-edibles, CBD-oil and extracts, CBD-personal care products, CBD-smoke & vape products, CBD-supplements, CBD-pet products, and other CBD-products. The CBD-edibles segment is estimated to account for the largest share of the CBD-infused products market in 2021. The large share of this segment is mainly attributed to the growing popularity of recreational cannabis, increasing demand for food infused by cannabis such as THC and CBD, rising adoption of CBD in different verticals such as confectionery, bakery, etc., and cannabis consumer are looking for alternatives to smoking cannabis. Also, the increasing use of CBD-edibles to treat psychiatric disorders, neurological disorders, and cancer, along with pain control, is expected to drive the demand for CBD-edibles. However, it is also expected to grow at the highest CAGR during the forecast period.

Based on distribution channel, the CBD-infused products market is segmented into offline and online stores. The offline stores segment is estimated to account for the largest share of the CBD-infused products market in 2021. The large share of this segment is mainly attributed to the perception of purchasing authentic and good quality products. However, the online store segment is expected to grow at the highest CAGR during the forecast period. The rapid growth of this segment is mainly attributed to the ease of convenience and rapid penetration of CBD-infused products on E-commerce platforms. Also, the availability of CBD-infused drinks on leading online platforms is playing a crucial role in the CBD-infused products market.

Geographically, the market is segmented into five major regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The North American region is estimated to account for the largest share of the CBD-infused products market in 2021. The large share of this region is primarily attributed to the ease of accessibility, technological advancements in CBD-infused products production and processing, a large base of CBD consumers, changing perceptions towards CBD consumption for both medical and recreational purposes, growing awareness regarding various medical benefits of CBD among users, and increasing investments from leading players.

CBD Key Players

The key players operating in the CBD-infused products market are Canopy Growth Corporation (Canada), Aphria, Inc. (Canada), Aurora Cannabis Inc. (Canada), Docklight Brands, Inc. (U.S.), Maricann Inc. (Canada), Tilray, Inc. (Canada), GW Pharmaceuticals plc (U.K.), VIVO Cannabis Inc. (Canada), Cresco Labs, Inc. (U.S.), Tauriga Sciences, Inc. (U.S.), MariMed Inc. (U.S.), CV Sciences, Inc. (U.S.), Puration, Inc. (U.S.), Kona Gold Solutions Inc. (U.S.), Bhang Inc. (U.S.), DT Brands & Co (N.I.) Ltd. (U.S.), Forest Coffee Trading Co. (U.S.), G&Juice (U.S.), Honeydrop Beverages Inc. (U.S.), and Elixinol Global Limited (Australia).

Story Continues